Since loss of functional NF1 in normal Schwann cells is an initiating event in the formation of plexiform neurofibroma, and ultimately, in malignant transformation, we challenged the neurofibromin-reduced and control cells with standard of care MEK inhibitor selumetinib. Here, MAP2K7 is linked to plexiform neurofibroma.